Disease · MONDO_0004975
Comparisons in its trials245
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 245
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Galantamine vs Placebo: serious adverse events | 129 of 1,024 | 123 of 1,021 | 2,045 | NCT00679627 | Trial comparisons |
| Donanemab vs Placebo: deaths from any cause | 16 of 853 | 10 of 874 | 1,727 | NCT04437511 | Trial comparisons |
| Donanemab vs Placebo: serious adverse events | 148 of 853 | 138 of 874 | 1,727 | NCT04437511 | Trial comparisons |
| Donanemab vs Placebo: Number or Participants With Anti-Donanemab Antibodies | 693 of 793 | 48 of 821 | 1,614 | NCT04437511 | Trial comparisons |
| Idalopirdine 60 mg vs Idalopirdine 60 mg + Memantine: deaths from any cause | 11 of 1,462 | 0 of 101 | 1,563 | NCT02079246 | Trial comparisons |
| Idalopirdine 60 mg vs Idalopirdine 60 mg + Memantine: serious adverse events | 91 of 1,462 | 2 of 101 | 1,563 | NCT02079246 | Trial comparisons |
| Solanezumab vs Placebo: serious adverse events | 299 of 734 | 308 of 723 | 1,457 | NCT01127633 | Trial comparisons |
| Donepezil SR 23 mg vs Donepezil IR 10 mg: serious adverse events | 80 of 963 | 45 of 471 | 1,434 | NCT00478205 | Trial comparisons |
| Bapineuzumab vs Placebo: serious adverse events | 137 of 654 | 77 of 439 | 1,093 | NCT00676143 | Trial comparisons |
| Aducanumab vs Placebo: deaths from any cause | 3 of 681 | 0 of 343 | 1,024 | NCT05310071 | Trial comparisons |
| Aducanumab vs Placebo: serious adverse events | 59 of 681 | 23 of 343 | 1,024 | NCT05310071 | Trial comparisons |
| Global - DBT Period: Gantenerumab vs Global - DBT Period: Placebo: DBT Period: Number of Participants With Injection-Site Reactions | 94 of 503 | 43 of 481 | 984 | NCT03444870 | Trial comparisons |
| Global - DBT Period: Gantenerumab vs Global - DBT Period: Placebo: DBT Period: Number of Participants With at Least One Adverse Event (AE) | 454 of 503 | 423 of 481 | 984 | NCT03444870 | Trial comparisons |
| Placebo: DBT vs Gantenerumab: DBT: DBT Period: Number of Participants With AEs | 409 of 474 | 451 of 501 | 975 | NCT03443973 | Trial comparisons |
| Placebo: DBT vs Gantenerumab: DBT: DBT Period: Number of Participants With Injection-Site Reactions | 31 of 474 | 75 of 501 | 975 | NCT03443973 | Trial comparisons |
Global - DBT Period: Gantenerumab vs Global - DBT Period: Placebo: DBT Period: Number of Participants With at Least One Amyloid-Related Imaging Abnormalities-Edema (ARIA-E) Magnetic Resonance Imaging (MRI) Finding | 105 of 497 | 5 of 476 | 973 | NCT03444870 | Trial comparisons |
Global - DBT Period: Gantenerumab vs Global - DBT Period: Placebo: DBT Period: Number of Participants With at Least One Amyloid-Related Imaging Abnormalities-Haemosiderin Deposition (ARIA-H) MRI Finding | 40 of 497 | 6 of 476 | 973 | NCT03444870 | Trial comparisons |
| Placebo: DBT vs Gantenerumab: DBT: DBT Period: Number of Participants With ARIA-H Confirmed by MRI | 57 of 470 | 109 of 496 | 966 | NCT03443973 | Trial comparisons |
| Placebo: DBT vs Gantenerumab: DBT: DBT Period: Number of Participants With ARIA-E Confirmed by MRI | 18 of 470 | 128 of 496 | 966 | NCT03443973 | Trial comparisons |
| Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205) vs Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205): deaths from any cause | 14 of 570 | 5 of 332 | 902 | NCT00566501 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004975/comparisons